LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response

Documenti analoghi

• Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
  di: Albershardt, Tina C, et al.
  Pubblicazione: (2015)
• First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
  di: Pollack, Seth M., et al.
  Pubblicazione: (2017)
• Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment
  di: Albershardt, Tina C, et al.
  Pubblicazione: (2015)
• A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
  di: Albershardt, Tina C, et al.
  Pubblicazione: (2014)
• A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
  di: Somaiah, Neeta, et al.
  Pubblicazione: (2020)